CytoSorbents is a leader in the treatment of life-threatening conditions in the intensive care unit and cardiac surgery using blood purification, with more than 300,000 CytoSorb® devices sold in more than 70 countries to date, and seeking U.S. FDA market authorization for an investigational product, DrugSorb-ATR®, to remove blood thinning drugs.